|
 |
European Pharmaceutical Contractor
|
Back in 1996, when the original publisher of EPC invited me to become the Editor of the new magazine, I hardly anticipated the impact that the magazine would have. From a rather specialist publication it has developed into a broad ranging publication with editorial covering the whole waterfront of pharmaceutical development and beyond. In the 25 issues since, we have covered issues ranging from facts and figures about the CRO scene (perhaps my specialty), novel methods of drug discovery, electronic data capture, cutting-edge analytical techniques and literally hundreds more. Although the 'E' stands for European we have had special foci on Japan and other countries, including an article from Nelson Mandela, many articles from and about the US, as well as many looking at the developing industry in Eastern Europe and Scandinavia.
We have not neglected the vital areas of regulatory affairs or intellectual property, while we usually find room for an article on the commercial aspects of the pharmaceutical industry. It has sometimes been difficult to decide if an article is more suited to one of EPC's sister publications EBR or PMPS - but in the final analysis it has mattered little to our wide readership.
The publisher's staff have done much to make my job a pleasure, and much credit must go to the contributors themselves for keeping up such a high and lively standard. Nor must I forget the advertisers without whom EPC would not exist.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Ultra slim and ultra quick
More info >>
|
|
 |
